Table 6.

Univariable analysis for the association of baseline factors with BCR-free survival

	No. of patients	Hazard ratio	95% CI	p value*
Clinical data
Age	186	1.056	1.018–1.096	0.004
iPSA	184	1.021	1.007–1.035	0.003
Pathological data
Gleason score in surgical specimen, no., n = 186
6–7	133	Reference
8–10	53	5.097	3.013–8.625	< 0.001
Pathological stage, no., n = 186
pT status
2	92	Reference
≥ 3	94	2.935	1.665–5.173	< 0.001
pN status
0	154	Reference
1	32	3.378	1.901–6.000	< 0.001
Surgical margin, no., n = 180
Negative	152	Reference
Positive	28	3.421	1.890–6.193	< 0.001
Imaging parameters
miTNM classification, no., n = 186
miT status
2	125	Reference
≥ 3a	61	2.811	1.673–4.722	< 0.001
miN status
No LN metastasis	168	Reference
With LN metastasis	18	2.691	1.311–5.527	0.007
SUVmean of prostatic lesions	183	1.019	1.002–1.036	0.028
SUVmean of prostatic lesions, no. n = 183
< median	91	Reference
≥ median	92	1.752	1.030–2.981	0.039
SUVmax of prostatic lesions	183	1.015	1.004–1.026	0.008
SUVmax of prostatic lesions, no. n = 183
< median	91	Reference
≥ median	92	1.744	1.025–2.968	0.040
TV of prostatic lesions	183	0.948	0.909–0.988	0.011
TV of prostatic lesions, no., n = 183
< median	91	Reference
≥ median	92	0.987	0.587–1.661	0.962
TL of prostatic lesions	183	1.003	1.000–1.006	0.072
TL of prostatic lesions, no., n = 183
< median	91	Reference
≥ median	92	0.957	0.568–1.612	0.869

BCR biochemical recurrence, CI confidence interval, iPSA initial PSA, IQR interquartile range, LN lymph node, PET positron emission tomography, PSA prostate-specific antigen, PSMA prostate-specific membrane antigen, SUV standardized uptake value, TL total lesion, TV tumor volume

*Significant associations are given in bold